Crick
HomeTrialsGenesDrugs23andMeGraphBlogContact
  • Home
  • Trials
  • Genes
  • Drugs
  • 23andMe
  • Graph
  • Blog
  • Contact
Crick

An open-source clinical intelligence platform. Explore clinical trials, gene networks, and molecular structures using public data sources.

Data Sources

  • ClinicalTrials.gov
  • OpenTargets
  • ClinVar
  • PubChem

Links

  • Contact
  • About
  • Privacy

© 2026 Crick. All rights reserved.

Crick is for educational purposes only. Not medical advice.

Results for “KRAS G12C Mutation”

167 trials

Filters

Phase
Early Phase 1
Phase 1
Phase 2
Phase 3
Phase 4
Status
Recruiting
Active, Not Recruiting
Not Yet Recruiting
Completed
Enrolling by Invitation

Showing 20 of 167 results

Testing effectiveness (Phase 2)Ended earlyNCT06024174
What this trial is testing

BMS-986466 With Adagrasib With or Without Cetuximab in Participants With Kirsten Rat Sarcoma Virus Glycine 12 to Cysteine (KRAS G12C)-Mutant Solid Tumors

Who this might be right for
Advanced Solid Tumors
Bristol-Myers Squibb 5
Early research (Phase 1)Looking for participantsNCT06659341
What this trial is testing

A Phase I Study of BAY3498264 Given Together With Sotorasib in Participants Who Have Advanced Solid Cancers With Specific Genetic Changes Called KRASG12C Mutation

Who this might be right for
Advanced Solid Tumors Harboring KRAS G12C Mutation
Bayer 104
Testing effectiveness (Phase 2)Active Not RecruitingNCT04699188
What this trial is testing

Study of JDQ443 in Patients With Advanced Solid Tumors Harboring the KRAS G12C Mutation

Who this might be right for
KRAS G12C Mutant Solid TumorsCarcinoma, Non-Small-Cell LungCarcinoma, Colorectal+7 more
Novartis Pharmaceuticals 344
Testing effectiveness (Phase 2)Ended earlyNCT05492045
What this trial is testing

Evaluate D-1553 in Combination Therapy in Non-Small Cell Lung Cancer

Who this might be right for
NSCLC
InventisBio Co., Ltd 22
Early research (Phase 1)Looking for participantsNCT06807619
What this trial is testing

Sotorasib in People With Brain Tumors

Who this might be right for
Brain Tumor
Memorial Sloan Kettering Cancer Center 16
Testing effectiveness (Phase 2)Active Not RecruitingNCT03600883
What this trial is testing

A Phase 1/2, Study Evaluating the Safety, Tolerability, PK, and Efficacy of Sotorasib (AMG 510) in Subjects With Solid Tumors With a Specific KRAS Mutation (CodeBreaK 100)

Who this might be right for
KRAS p.G12C Mutant Advanced Solid Tumors
Amgen 713
Testing effectiveness (Phase 2)Looking for participantsNCT07252739
What this trial is testing

KEYMAKER-U01 Substudy 01J: A Study of Pembrolizumab Plus MK-1084 in Participants With Non-Small Cell Lung Cancer (NSCLC) With Kirsten Rat Sarcoma Viral Oncogene Homolog (KRAS) G12C Mutations (MK-3475-01J/KEYMAKER-U01J)

Who this might be right for
Malignant Neoplasm
Merck Sharp & Dohme LLC 130
Early research (Phase 1)Study completedNCT04330664
What this trial is testing

Adagrasib in Combination With TNO155 in Patients With Cancer (KRYSTAL 2)

Who this might be right for
Advanced CancerMetastatic CancerMalignant Neoplastic Disease
Mirati Therapeutics Inc. 86
Not applicableNot Yet RecruitingNCT07396090
What this trial is testing

Study of KRAS-Specific Vaccine in Patients With KRAS-Mutated Solid Tumors

Who this might be right for
Advanced Solid Tumor
Cancer Institute and Hospital, Chinese Academy of Medical Sciences 13
Large-scale testing (Phase 3)Looking for participantsNCT06416410
What this trial is testing

JAB-21822 Combined With JAB-3312 Compared SOC in the First Line for Treatment of Advanced Non-small Cell Lung Cancer With KRAS p.G12C Mutation

Who this might be right for
Advanced Non-squamous Non-small-cell Lung CancerMetastatic Non-squamous Non Small Cell Lung Cancer
Allist Pharmaceuticals, Inc. 392
Testing effectiveness (Phase 2)UnknownNCT05451056
What this trial is testing

An Open-label, Phase 2trial of Sotorasib in KRAS G12C-mutant Non-small-cell Lung Cancer(NSCLC) Patients and a Translational Study to Find Acquired Resistance Mechanism to Sotorasib

Who this might be right for
Non Small Cell Lung Cancer
Yonsei University 37
Large-scale testing (Phase 3)Looking for participantsNCT06890598
What this trial is testing

Study of Olomorasib (LY3537982) in Combination With Standard of Care in Participants With Resected or Unresectable KRAS G12C-mutant Non-Small Cell Lung Cancer

Who this might be right for
Carcinoma, Non-Small-Cell Lung
Eli Lilly and Company 700
Testing effectiveness (Phase 2)WithdrawnNCT05815186
What this trial is testing

Ladarixin With Sotorasib in Advanced NSCLC - Phase II

Who this might be right for
Advanced Non-small Cell Lung Cancer With KRAS G12C Mutation
NYU Langone Health
Testing effectiveness (Phase 2)Active Not RecruitingNCT05009329
What this trial is testing

JAB-21822 in Adult Patients With Advanced Solid Tumors Harboring KRAS p.G12C Mutation in China

Who this might be right for
NSCLCSolid Tumor
Allist Pharmaceuticals, Inc. 315
Testing effectiveness (Phase 2)Looking for participantsNCT07198841
What this trial is testing

IBI351 Plus Cetuximab β in Untreated Advanced Non-small Cell Lung Cancer With KRAS G12C Mutation

Who this might be right for
Lung Cancer (Non-Small Cell)
Guangdong Association of Clinical Trials 48
Early research (Phase 1)Looking for participantsNCT06447662
What this trial is testing

Learn About the Study Medicine PF-07934040 When Given Alone or With Other Anti-cancer Therapies in People With Advanced Solid Tumors That Have a Genetic Mutation.

Who this might be right for
Carcinoma, Pancreatic DuctalColorectal NeoplasmsCarcinoma, Non-Small-Cell Lung
Pfizer 330
Early research (Phase 1)Study completedNCT06235983
What this trial is testing

LY3537982 in Chinese Participants With Advanced Solid Tumors

Who this might be right for
Advanced Solid Tumors
Eli Lilly and Company 12
Early research (Phase 1)Study completedNCT04006301
What this trial is testing

First-in-Human Study of JNJ-74699157 in Participants With Tumors Harboring the KRAS G12C Mutation

Who this might be right for
NeoplasmsAdvanced Solid TumorsNon-small Cell Lung Cancer+1 more
Janssen Research & Development, LLC 10
Testing effectiveness (Phase 2)Not Yet RecruitingNCT06435455
What this trial is testing

GH21 Combined With D-1553 in KRAS G12C Mutant Advanced Solid Tumors

Who this might be right for
Locally Advanced or Metastatic Solid Tumors Harboring KRAS G12C Mutation
Suzhou Genhouse Bio Co., Ltd. 126
Testing effectiveness (Phase 2)WithdrawnNCT05251038
What this trial is testing

Study of Sotorasib Combined With Chemotherapy for Second Line Treatment of Pancreas Cancer

Who this might be right for
Pancreatic CancerUnresectable Pancreatic CancerMetastatic Pancreatic Cancer+1 more
Devalingam Mahalingam
Load More Results